It is estimated that as much as 1.7% of the World’s population are living with Ischaemic heart disease, with a high risk of MI resulting in death or progression to heart failure; described by patients as
“It’s like growing old overnight, without gradual ageing giving you the chance to get used to it.”
The need for pharmacotherapy to add to the acute treatment of the heart after MI by cardiologists is clear. In the words of the European Society of Cardiology
“..still there is no therapy aimed at reducing (heart) injury that is clearly associated with improved clinical outcomes.”
Forcefield plans to meet this call to action as a pioneer of best-in-class therapeutics to preserve and protect heart function.